Effectiveness and safety of turmeric for the treatment of COVID-19: An updated systematic review and meta-analysis of randomized controlled trials
Complementary Therapies in Medicine · 2025-12 · 95 · 103295
DOI: 10.1016/j.ctim.2025.103295 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Complementary Therapies in Medicine, 2025-12. Verfasst von Ratree Sawangjit und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials and Evidence-Based Syntheses Research Unit (CTEBs RU), Mahasarakham University, Maha Sarakham, Thailand; Department of Clinical Pharm…. Hauptthemen laut MEDLINE: Curcuma, COVID-19, COVID-19 Drug Treatment, Plant Extracts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Higher Education, Science, Research and Innovation, Thailand, Mahasarakham University.
Abstract (Originalsprache)
We conducted a comprehensive and updated systematic review and meta-analysis (SR-MA) to determine the effectiveness and safety of turmeric in patients with coronavirus disease 2019 (COVID-19). Multiple databases were searched from inception to July 31, 2024, for randomized controlled trials (RCTs) assessing turmeric in mild to severe COVID-19. This SR-MA uniquely includes recent trials conducted alongside modern antiviral-based regimens and explores effect modifiers by disease severity, comorbidity, formulation, and treatment duration. Twenty-three RCTs with 1407 participants were included, making this the largest synthesis to date. Most studies (17/23, 73.9 %) enrolled hospitalized patients; over half involved mild to moderate cases. The most common intervention was nano-curcumin 160-240 mg/day (39 %), used as an adjunct to standard care. Nine studies were rated high risk of bias (ROB). Meta-analysis showed turmeric significantly reduced all-cause mortality (Relative risk (RR) = 0.39; 95 % confidence interval (95 %CI): 0.23-0.67; I² = 0 %; n = 8 RCTs; moderate certainty), suggesting a 61 % reduction in risk of death. It also reduced the need for intubation/mechanical ventilation (RR = 0.35; 95 %CI: 0.17-0.72) and clinical deterioration (RR=0.36; 95 %CI: 0.22-0.59), while improving overall symptom resolution (RR = 1.36; 95 %CI: 1.16-1.59). These results remained robust after excluding high ROB studies. Adverse events, mostly mild gastrointestinal symptoms, were comparable to placebo. In conclusion, turmeric, particularly bioavailability-enhanced nano-curcumin, provides meaningful clinical benefits and favorable safety profile as adjunctive therapy for COVID-19. Further large-scale, high-quality, multicenter RCTs are warranted to confirm its therapeutic potential, particularly in resource-limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trials and Evidence-Based Syntheses Research Unit (CTEBs RU), Mahasarakham University, Maha Sarakham, Thailand; Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thail…
- Pakchongnana Hospital, Pakchong, Nakhon Ratchasima, Thailand.
- Phimai Hospital, Phimai, Nakhon Ratchasima, Thailand.
- Faculty of Pharmacy, Nakhonratchasima College, Nakhonratchasima, Thailand.
- Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla, Thailand; Phytomedicine and Pharmaceutical Biotechnology Excellence Center - PP…
- Department of Thai Traditional and Alternative Medicine, Ministry of Public Health, Thailand.
Förderung
- Ministry of Higher Education, Science, Research and Innovation, Thailand
- Mahasarakham University
Zitieren
APA
Sawangjit, R., Sadoyu, S., Manosanthipaibul, S., Teerawattanapong, N., Puttarak, P., Wanaratna, K., Charoensup, R., Hiransai, P., Meetam, T., & Chaiyakunapruk, N. (2025). Effectiveness and safety of turmeric for the treatment of COVID-19: An updated systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine, 95, 103295. https://doi.org/10.1016/j.ctim.2025.103295
Vancouver
Sawangjit R, Sadoyu S, Manosanthipaibul S, Teerawattanapong N, Puttarak P, Wanaratna K, et al. Effectiveness and safety of turmeric for the treatment of COVID-19: An updated systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. 2025;95:103295. doi:10.1016/j.ctim.2025.103295
BibTeX
@article{Sawangjit2025,
author = {Sawangjit, Ratree and Sadoyu, Saranrat and Manosanthipaibul, Siripong and Teerawattanapong, Nattawat and Puttarak, Panupong and Wanaratna, Kulthanit and Charoensup, Rawiwan and Hiransai, Poonsit and Meetam, Thunyaluk and Chaiyakunapruk, Nathorn},
title = {Effectiveness and safety of turmeric for the treatment of COVID-19: An updated systematic review and meta-analysis of randomized controlled trials},
journal = {Complementary Therapies in Medicine},
year = {2025},
volume = {95},
pages = {103295},
doi = {10.1016/j.ctim.2025.103295}
}
EUVIMED